



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI   
[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show 20 Sort by Send to

Text Version

All: 1 Review: 1 

## Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy 

E-Utilities

## PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

## Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Magnes Res.](#) 2005 Jun;18(2):123-6.

[Related Articles, Links](#)



## Magnesium therapy for nephrolithiasis.

[Massey L.](#)

Food Science and Human Nutrition, Washington State University, PO Box 1495, Spokane WA 99210-1495, USA. [massey@wsu.edu](mailto:massey@wsu.edu)

**PURPOSE:**Critically evaluate the experimental evidence and clinical trial outcomes as the basis for use of magnesium (Mg) supplements as therapy for calcium oxalate nephrolithiasis. **MATERIALS AND METHODS:** Literature search of MedLine and Web of Science through January 2005; articles cited in papers found by searches. **RESULTS:** Magnesium inhibits calcium oxalate crystallization in human urine and model systems. Magnesium also inhibits absorption of dietary oxalate from the gut lumen. Three early trials of Mg oxide (MgO) and Mg hydroxide (Mg(OH)<sub>2</sub>) reported lower rates of recurrent stone formation. However in a double-blind, randomized, placebo-controlled trial with more carefully selected patients, there was no significant difference between recurrence rates with 650 or 1300 mg MgO daily and the placebo. Another trial reported 391 mg (21 meq) Mg daily as a mixed salt, Mg potassium citrate, reduced calcium stone recurrence by 90%, similar to potassium citrate, but with better gastrointestinal tolerance. The failure of MgO and Mg(OH)<sub>2</sub> as sole therapy may be related to poor absorption and low rates of Mg deficiency in the patient populations tested. **CONCLUSIONS:** Clinical trial evidence does not justify the use of MgO or Mg(OH)<sub>2</sub> as a sole therapy for calcium oxalate kidney stones in a general patient population. However, the addition of magnesium to potassium citrate therapy improves outcomes. Clinical trials should focus on patients who are likely to be Mg deficient.

Publication Types:

- [Review](#)

PMID: 16100850 [PubMed - indexed for MEDLINE]

---

Display  Show  Sort by  Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jun 6 2006 06:32:22